CryoLife Inc. (NYSE:CRY) has earned an average recommendation of “Buy” from the six brokerages that are covering the company. One equities research analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $15.25.
A number of research firms have recently issued reports on CRY. Zacks Investment Research raised CryoLife from a “hold” rating to a “strong-buy” rating and set a $18.00 target price on the stock in a report on Friday, August 12th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $16.00 price objective on shares of CryoLife in a report on Wednesday, July 27th. Lake Street Capital started coverage on CryoLife in a report on Wednesday, June 15th. They set a “buy” rating and a $15.00 price objective on the stock. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of CryoLife in a report on Monday, June 20th.
Shares of CryoLife (NYSE:CRY) opened at 17.41 on Tuesday. The firm has a 50 day moving average price of $16.72 and a 200-day moving average price of $13.18. The firm has a market capitalization of $593.86 million, a P/E ratio of 55.80 and a beta of 1.14. CryoLife has a 52 week low of $8.94 and a 52 week high of $18.64.
CryoLife (NYSE:CRY) last released its earnings results on Monday, July 25th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.11. The business had revenue of $47.10 million for the quarter, compared to analyst estimates of $35.50 million. CryoLife had a return on equity of 8.15% and a net margin of 5.80%. The company’s revenue for the quarter was up 32.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 earnings per share. Equities research analysts predict that CryoLife will post $0.34 EPS for the current fiscal year.
In other CryoLife news, Director C Elkins Ronald sold 2,000 shares of the business’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $14.00, for a total transaction of $28,000.00. Following the sale, the director now directly owns 103,586 shares in the company, valued at $1,450,204. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 6.08% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Chartwell Investment Partners LLC purchased a new stake in CryoLife during the second quarter worth approximately $16,488,000. Elk Creek Partners LLC increased its stake in CryoLife by 150.4% in the second quarter. Elk Creek Partners LLC now owns 486,875 shares of the company’s stock worth $2,917,000 after buying an additional 292,427 shares during the last quarter. BlackRock Fund Advisors increased its stake in CryoLife by 13.4% in the second quarter. BlackRock Fund Advisors now owns 1,863,006 shares of the company’s stock worth $22,002,000 after buying an additional 220,391 shares during the last quarter. Macquarie Group Ltd. increased its stake in CryoLife by 18.5% in the second quarter. Macquarie Group Ltd. now owns 1,014,361 shares of the company’s stock worth $11,980,000 after buying an additional 158,177 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new stake in CryoLife during the second quarter worth approximately $921,000. Institutional investors own 58.13% of the company’s stock.
CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.